ranibizumab-eqrn 0.3 MG in 0.05 ML Injection

RxCUI
2612675
RxNorm name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Display name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Full name
ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:24

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761165Cimerliranibizumab-eqrn351(k) InterchangeableRx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CIMERLIRANIBIZUMAB-EQRNCoherus BioSciences Ince0e23118-1490-a554-e053-2995a90ab90c2025-05-07Warnings, Adverse reactionsExact identifier
rxcui: 2612675
CIMERLIRANIBIZUMAB-EQRNSandoz Inc4b383d74-4830-4587-95f7-c32a39268df72024-06-17Warnings, Adverse reactionsExact identifier
rxcui: 2612675

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
e0e23118-1490-a554-e053-2995a90ab90cranibizumab-eqrn 0.3 MG per 0.05 ML InjectionSY12These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet20250507
e0e23118-1490-a554-e053-2995a90ab90cranibizumab-eqrn 6 MG/ML per 0.05 ML InjectionSY12These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet20250507
e0e23118-1490-a554-e053-2995a90ab90c0.05 ML ranibizumab-eqrn 6 MG/ML InjectionSCD12These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet20250507
e0e23118-1490-a554-e053-2995a90ab90cranibizumab-eqrn 0.3 MG in 0.05 ML InjectionPSN12These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet20250507
4b383d74-4830-4587-95f7-c32a39268df7ranibizumab-eqrn 0.3 MG in 0.05 ML InjectionPSN3These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20240617
4b383d74-4830-4587-95f7-c32a39268df7ranibizumab-eqrn 6 MG/ML per 0.05 ML InjectionSY3These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20240617
4b383d74-4830-4587-95f7-c32a39268df70.05 ML ranibizumab-eqrn 6 MG/ML InjectionSCD3These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20240617
4b383d74-4830-4587-95f7-c32a39268df7ranibizumab-eqrn 0.3 MG per 0.05 ML InjectionSY3These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20240617